Gonzalez Angel, Icen Murat, Kremers Hilal Maradit, Crowson Cynthia S, Davis John M, Therneau Terry M, Roger Veronique L, Gabriel Sherine E
Department of Internal Medicine, Caritas St. Elizabeth's Medical Center, Boston, Massachusetts, USA.
J Rheumatol. 2008 Jun;35(6):1009-14. Epub 2008 Apr 15.
OBJECTIVE: We previously demonstrated a widening in the mortality gap between subjects with rheumatoid arthritis (RA) and the general population. We examined the contribution of rheumatoid factor (RF) positivity on overall mortality trends and cause-specific mortality. METHODS: A population-based RA incidence cohort (1955-1995, and aged >or= 18 yrs) was followed longitudinally until death or January 1, 2006. The underlying cause of death as coded from national mortality statistics and grouped according to ICD-9/10 chapters was used to define cause-specific mortality. Expected cause-specific mortality rates were estimated by applying the age-, sex-, and calendar-year-specific mortality rates from the general population to the RA cohort. Poisson regression was used to model the observed overall and cause-specific mortality rates according to RF status, accounting for age, sex, disease duration, and calendar year. RESULTS: A cohort of 603 subjects (73% female; mean age 58 yrs) with RA was followed for a mean of 16 years, during which 398 died. Estimated survival at 30 years after RA incidence was 26.0% in RF+ RA subjects compared to 36.0% expected (p < 0.001), while in RF- RA subjects, estimated survival was 29.1% compared to 28.3% expected (p = 0.9). The difference between the observed and the expected mortality in the RF+ RA subjects increased over time, resulting in a widening of the mortality gap, while among RF- RA subjects, observed mortality was very similar to the expected mortality over the entire time period. Among RF+ RA subjects, cause-specific mortality was higher than expected for cardiovascular [relative risk (RR) 1.50; 95% confidence interval (CI) 1.22, 1.83] and respiratory diseases [RR 3.49; 95% CI 2.51, 4.72]. Among RF- RA subjects, no significant differences were found between observed and expected cause-specific mortality. CONCLUSION: The widening in the mortality gap between RA subjects and the general population is confined to RF+ RA subjects and largely driven by cardiovascular and respiratory deaths.
J Rheumatol. 2008-6
Arthritis Rheum. 2007-11
Arthritis Care Res (Hoboken). 2010-3
Arthritis Rheum. 2003-1
J Rheumatol. 1999-12
Arthritis Rheum. 1993-8
J Inflamm Res. 2025-6-17
Nat Rev Immunol. 2023-5
Pharmaceuticals (Basel). 2022-9-17
Nat Rev Rheumatol. 2021-1
Arthritis Rheum. 2007-11
N Engl J Med. 2007-6-7
Rheum Dis Clin North Am. 2004-11
J Rheumatol. 2003-9